Cd40-targetting antibodies and uses thereof
AssigneeUtc Tyherapeutics (Shangnai) Co., Ltd.
InventorsYangbing ZHAO, Xiaojun LIU, Gengzhen Zhu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are CD40-targetting antibodies and uses thereof. Disclosed herein are novel antigen-binding proteins that specifically bind CD40 and antigen-binding fragments thereof. Disclosed herein are also fusion proteins comprising a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) and a second domain that activates an immune effector cell (e.g., a T cell), wherein the first domain comprises antigen-binding proteins that specifically bind CD40 or antigen-binding fragments thereof disclosed herein.
Claims20
An antigen-binding protein that specifically binds CD40, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprising a heavy chain CDR1 (HCDR1), a heavy chain CDR2 (HCDR2) and a heavy chain CDR3 (HCDR3);
- and the VL comprising a light chain CDR1 (LCDR1), a light chain CDR2 (LCDR2) and a light chain CDR3 (LCDR3), wherein
- a) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 2, 3 and 4, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 6, 7, and 8, respectively;
- b) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 11, 12 and 13, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 15, 16, and 17, respectively;
- c) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 2, 3 and 20, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 22, 23, and 24, respectively;
- d) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 27, 28 and 29, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 31, 32, and 33, respectively;
- e) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 36, 37 and 38, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 40, 41, and 42, respectively;
- f) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 45, 46 and 47, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 49, 50, and 51, respectively;
- g) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 54, 55 and 56, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 58, 41, and 59, respectively;
- h) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 62, 63 and 64, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 66, 67, and 68, respectively;
- or
- i) the HCDR1, HCDR2 and HCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 45, 46 and 47, respectively;
- and the LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence as set forth in SEQ ID NOs:
- 71, 72, and 51, respectively.
Dependencies are inferred from the claim text.